Please use this identifier to cite or link to this item: https://hdl.handle.net/2440/44844
Citations
Scopus Web of Science® Altmetric
?
?
Full metadata record
DC FieldValueLanguage
dc.contributor.authorChidlow, G.en
dc.contributor.authorWood, J.en
dc.contributor.authorCasson, R.en
dc.date.issued2007en
dc.identifier.citationDrugs, 2007; 67(5):725-759en
dc.identifier.issn0012-6667en
dc.identifier.issn0012-6667en
dc.identifier.urihttp://hdl.handle.net/2440/44844-
dc.descriptionCopyright © 2007 Adis Data Information BV. All rights reserved.en
dc.description.abstractGlaucoma represents a group of neurodegenerative diseases characterised by structural damage to the optic nerve and slow, progressive death of retinal ganglion cells (RGCs). Elevated intraocular pressure is traditionally considered to be the most important risk factor for glaucoma, and treatment options for the disease have hitherto been limited to its reduction. However, visual field loss and RGC death continue to occur in patients with well controlled intraocular pressures and, thus, a consensus has recently emerged that additional treatment strategies are needed. One such strategy is pharmacological neuroprotection, which in the context of glaucoma, refers to the situation in which a drug is deployed to interact with neuronal or glial elements within the retina/optic nerve head and thereby facilitate the survival of RGCs. The advent of animal models of chronic glaucoma has enhanced our understanding of many of the pathological processes occurring in glaucoma and, in doing so, described logical targets for pharmacological intervention. Such targets, which have been manipulated with varying degrees of success in relevant animal paradigms include glutamate receptors, autoimmune elements, neurotrophin deprivation, nitric oxide synthesis, oxidative stress products, sodium and calcium channels, heat shock proteins and apoptotic pathways. With exciting data now emerging from many research laboratories, it is obvious that pharmacological neuroprotection for glaucoma without doubt represents an exciting development in the search for a treatment modality for this debilitating disease.en
dc.description.statementofresponsibilityGlyn Chidlow, John P.M. Wood and Robert J. Cassonen
dc.language.isoenen
dc.publisherAdis International Ltden
dc.subjectAnimals; Humans; Glaucoma; Neuroprotective Agents; Models, Biologicalen
dc.titlePharmacological neuroprotection for glaucomaen
dc.typeJournal articleen
dc.identifier.doi10.2165/00003495-200767050-00006en
pubs.publication-statusPublisheden
dc.identifier.orcidChidlow, G. [0000-0001-7371-0239]en
dc.identifier.orcidCasson, R. [0000-0003-2822-4076]en
Appears in Collections:Medicine publications

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.